Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
Biomarkers, Tumor
Biopsy
Breast Neoplasms
/ drug therapy
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Disease Models, Animal
Female
Humans
Immunoconjugates
/ pharmacology
Immunomodulation
/ drug effects
Iron
/ metabolism
Lymphocytes, Tumor-Infiltrating
/ immunology
Mice
Nanoparticles
Protein Binding
T-Lymphocytes
/ drug effects
Tumor Burden
Tumor Microenvironment
/ drug effects
Xenograft Model Antitumor Assays
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
24
05
2019
accepted:
06
01
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
25
11
2020
Statut:
epublish
Résumé
The factors that influence nanoparticle fate in vivo following systemic delivery remain an area of intense interest. Of particular interest is whether labeling with a cancer-specific antibody ligand ("active targeting") is superior to its unlabeled counterpart ("passive targeting"). Using models of breast cancer in three immune variants of mice, we demonstrate that intratumor retention of antibody-labeled nanoparticles was determined by tumor-associated dendritic cells, neutrophils, monocytes, and macrophages and not by antibody-antigen interactions. Systemic exposure to either nanoparticle type induced an immune response leading to CD8
Identifiants
pubmed: 32232146
doi: 10.1126/sciadv.aay1601
pii: aay1601
pmc: PMC7096167
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Immunoconjugates
0
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
eaay1601Subventions
Organisme : NIGMS NIH HHS
ID : R25 GM109441
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Références
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
Clin Cancer Res. 2004 Apr 1;10(7):2499-511
pubmed: 15073130
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Cell Tissue Res. 2007 Nov;330(2):291-302
pubmed: 17874251
Int J Hyperthermia. 2018 Jun;34(4):373-381
pubmed: 28758530
Int J Exp Pathol. 2008 Apr;89(2):138-58
pubmed: 18336531
Blood. 2004 Aug 15;104(4):1010-6
pubmed: 15126319
J Immunol. 2003 Oct 15;171(8):4352-8
pubmed: 14530360
J Immunol. 2012 Oct 1;189(7):3430-8
pubmed: 22956577
Sci Technol Adv Mater. 2015 Apr 28;16(2):023501
pubmed: 27877761
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Onco Targets Ther. 2016 Sep 23;9:5847-5854
pubmed: 27713638
Nat Nanotechnol. 2017 May;12(4):387-393
pubmed: 27992410
Breast Cancer (Auckl). 2010 May 20;4:35-41
pubmed: 20697531
Mol Pharm. 2011 Dec 5;8(6):2101-41
pubmed: 21974749
PLoS One. 2015 Feb 19;10(2):e0115636
pubmed: 25695795
Sci Rep. 2018 Mar 20;8(1):4916
pubmed: 29559734
Nanotechnology. 2009 Sep 30;20(39):395103
pubmed: 19726837
Blood. 2003 May 15;101(10):4155-63
pubmed: 12531806
Toxicol Appl Pharmacol. 2016 May 15;299:78-89
pubmed: 26739622
Curr Rheumatol Rev. 2014;10(1):22-34
pubmed: 25229496
Nat Commun. 2016 Dec 19;7:13818
pubmed: 27991503
Front Cell Infect Microbiol. 2014 May 12;4:51
pubmed: 24860789
Nano Lett. 2009 May;9(5):1909-15
pubmed: 19344179
Cancer Res. 2014 Oct 1;74(19):5561-71
pubmed: 25228655
J Immunol. 1994 May 15;152(10):5000-8
pubmed: 8176217
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Bioconjug Chem. 2008 Jun;19(6):1211-8
pubmed: 18517234
J Vis Exp. 2013 Jun 23;(76):
pubmed: 23851980
Blood. 1975 Jul;46(1):51-64
pubmed: 1131426
Mol Pharm. 2014 Apr 7;11(4):1250-8
pubmed: 24521246
Nat Commun. 2017 Oct 3;8(1):777
pubmed: 28974673
Annu Rev Med. 2015;66:111-28
pubmed: 25587647
Endocrinology. 2010 Feb;151(2):458-65
pubmed: 20016026
Nanomedicine (Lond). 2012 Nov;7(11):1697-711
pubmed: 22830502
J Immunol. 2006 Dec 1;177(11):7740-9
pubmed: 17114445
Drugs. 2015 Sep;75(14):1601-11
pubmed: 26323338
Adv Drug Deliv Rev. 2014 Feb;66:2-25
pubmed: 24270007